New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis
نویسندگان
چکیده
منابع مشابه
Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
Background: Bone mineral density (BMD) changes during the course of rheumatoid arthritis (RA). The present study was designed to investigate the status of BMD in patients with RA treated with anti-rheumatic drugs. Methods: BMD at the femoral neck (FN-BMD) and lumbar spine (LS-BMD) were measured by dual energy x-ray absorptiometry (DXA) method using Norland densitometer. Disease activity (DA) wa...
متن کاملResponse to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
INTRODUCTION The aim of this study was to compare the response between subsequent use of anti-tumor necrosis factor α (anti-TNF) agents and biologic disease-modifying anti-rheumatic drugs (bDMARD) with other mechanism of action (MOA) in rheumatoid arthritis (RA) patients with history of anti-TNF treatment as their first bDMARD. METHODS A retrospective chart review was conducted at eight commu...
متن کاملA mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis.
BACKGROUND The short-term efficacy of biological disease modifying anti-rheumatic drugs (bDMARDs) for the treatment of established moderate to severe rheumatoid arthritis (RA) has been demonstrated by various randomized placebo or active treatment controlled trials. However, there is a lack of direct comparison of these agents. SCOPE To compare the short-term efficacy of nine bDMARDs - abatac...
متن کاملBiologic Disease-Modifying Antirheumatic Drugs
1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Just...
متن کاملKey words: rheumatoid arthritis, treatment, disease-modifying anti-rheumatic drugs, anti-TNF agents, new therapies
1Rheumatology Unit, Department of Experimental and Clinical Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy; 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; 3Department of Rheumatology, University of Perugia, Italy; 4Department of Rheumatology, Policlinico Le Scotte, University of Siena, Italy. Andrea Calabrò, M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Clinical Immunology
سال: 2009
ISSN: 0911-4300,1349-7413
DOI: 10.2177/jsci.32.149